RecruitingNCT04746625

Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment


Sponsor

Sophysa

Enrollment

126 participants

Start Date

Jun 4, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The SAPPHYRE study is an ambispective (retrospective and prospective) PMCF study with the objective to evaluate the safety and performance of the Polaris® 24 adjustable valve system in the treatment of 126 patients with hydrocephalus.


Eligibility

Inclusion Criteria5

  • Patient implanted with the Polaris® 24 adjustable valve system for the following reasons:
  • Primo implant of a valve shunt-based derivation system, or as a
  • Replacement of another valve -based shunt system, or
  • Endoscopic ventriculostomy (EVT) failure
  • Patient having given his/her informed consent prior to inclusion in this study, as per local regulations

Exclusion Criteria3

  • Confirmed or suspected infections along the length of the shunt (meningitis, ventriculitis, peritonitis, septicemia or bacteremia) or any infection present in any part of the body
  • Patient on anticoagulant therapy, or presenting with bleeding diathesis, or with haemorrhagic CSF, as the presence of blood in the system could lead to an obstruction in the system
  • Ventriculo-atrial shunts in patient suffering from congenital cardiopathies or other malformations of the cardio-pulmonary system

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

La Timone Children's Hospital

Marseille, France

La Pitié Salpétrière Hospital

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04746625


Related Trials